TD Asset Management Inc Buys 11,658 Shares of Natera, Inc. $NTRA

TD Asset Management Inc grew its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 9.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 129,606 shares of the medical research company’s stock after purchasing an additional 11,658 shares during the period. TD Asset Management Inc’s holdings in Natera were worth $20,863,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in NTRA. Integrated Wealth Concepts LLC lifted its holdings in shares of Natera by 6.6% in the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after purchasing an additional 96 shares in the last quarter. NewEdge Advisors LLC lifted its stake in shares of Natera by 68.3% in the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after acquiring an additional 1,847 shares during the last quarter. Focus Partners Wealth increased its stake in Natera by 8.6% in the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after purchasing an additional 474 shares during the period. Sivia Capital Partners LLC purchased a new position in shares of Natera in the second quarter worth $298,000. Finally, Envestnet Asset Management Inc. raised its stake in Natera by 5.9% in the second quarter. Envestnet Asset Management Inc. now owns 172,022 shares of the medical research company’s stock worth $29,061,000 after buying an additional 9,651 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Natera Trading Down 3.7%

NASDAQ:NTRA opened at $208.04 on Friday. The firm’s fifty day simple moving average is $226.52 and its 200 day simple moving average is $203.85. Natera, Inc. has a twelve month low of $125.38 and a twelve month high of $256.36. The firm has a market capitalization of $28.78 billion, a price-to-earnings ratio of -135.97 and a beta of 1.64.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.81. The firm had revenue of $665.50 million during the quarter, compared to analysts’ expectations of $600.68 million. Natera had a negative return on equity of 16.71% and a negative net margin of 9.03%.During the same quarter in the prior year, the business earned ($0.41) EPS. On average, analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Activity

In other Natera news, insider John Fesko sold 17,806 shares of the business’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $234.74, for a total transaction of $4,179,780.44. Following the sale, the insider directly owned 177,591 shares in the company, valued at approximately $41,687,711.34. The trade was a 9.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Solomon Moshkevich sold 23,205 shares of Natera stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $234.74, for a total value of $5,447,141.70. Following the transaction, the insider owned 144,992 shares in the company, valued at approximately $34,035,422.08. This trade represents a 13.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 368,119 shares of company stock worth $85,956,782 over the last three months. Insiders own 5.63% of the company’s stock.

Key Stories Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Quarterly beat — Natera reported Q4 revenue of $665.5M and GAAP EPS of $0.35, well ahead of street estimates (revenue ~$600.7M, EPS loss consensus). The beat supports near-term growth expectations and underpins the stock’s recent strength. Natera Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Favorable clinical data — New Signatera MRD data presented at ASCO GU highlight potential utility across genitourinary cancers (including bladder preservation), which may expand clinical adoption and long-term revenue for Natera’s oncology franchise. Signatera MRD Data at ASCO GU
• Positive Sentiment: Trial results — Natera reported results from the SINERGY trial, another clinical datapoint that could support commercial adoption of its assays. Natera Announces Results From the SINERGY Trial
• Positive Sentiment: Analyst upgrades/targets — Robert W. Baird raised its price target to $257 (outperform) and Wells Fargo raised its target to $215 (equal weight), signaling some sell-side confidence in upside from current levels. Benzinga – Analyst Price Target Changes
• Neutral Sentiment: Full-year revenue guidance roughly in line with consensus — Management issued FY2026 revenue guidance (roughly $2.6B–$2.7B), which appears consistent with street expectations and reduces upside surprise potential from guidance alone. (See Q4 release for guidance details.) Natera Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Analyst consensus — Aggregated analyst coverage remains constructive (average “Moderate Buy”), which supports medium-term expectations but doesn’t preclude short-term volatility. Analyst Average Rating
• Negative Sentiment: Valuation and fundamentals concerns — Despite the beat, Natera still shows negative net margin and negative return on equity on a GAAP basis; combined with a high market capitalization and a recent run-up toward 52-week highs, investors may be taking profits. MarketBeat Q4 Coverage
• Negative Sentiment: Heavy intraday volume and selling pressure — Trading volume was well above average, consistent with a distribution day where some holders trimmed positions after the company’s strong quarter; that drove the stock lower despite the positives. (See intraday volume and price action for context.)

Wall Street Analyst Weigh In

Several brokerages have weighed in on NTRA. Piper Sandler upped their target price on Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. TD Cowen reaffirmed a “buy” rating on shares of Natera in a research report on Wednesday, January 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research note on Thursday, January 22nd. Canaccord Genuity Group restated a “buy” rating on shares of Natera in a research report on Monday, January 12th. Finally, Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and a consensus target price of $254.47.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.